Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2023-04-04 Director's Dealing
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-04-04 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-22 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-22 English
10-K
Annual Report FY 2022
2023-03-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing its financial results for the year ended December 31, 2022, and that the press release is furnished as an exhibit. The document itself does not contain the full financial results or detailed financial statements but rather announces the release of such information. The document length is under 5,000 characters and serves as a notification rather than the full report. Therefore, according to the 'Menu vs Meal' rule, this is an announcement of a report (press release of earnings) rather than the report itself. The appropriate classification for such a filing is Regulatory Filings (RNS), which is the fallback for miscellaneous filings including current reports like Form 8-K that announce events but do not contain full financial data.
2023-03-09 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events or material definitive agreements by a company. The text describes an extension of an option agreement between VYNE Therapeutics and Tay Therapeutics, including payment terms and forward-looking statements. It also includes a press release about regaining compliance with Nasdaq rules. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or earnings release. It is a regulatory filing announcing a material agreement and related corporate updates. Therefore, it fits best under Regulatory Filings (RNS). The document length (8732 characters) and content confirm it is a substantive filing, not just a brief announcement or certification.
2023-02-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.